Trials / Withdrawn
WithdrawnNCT02520245
Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study has been designed to collect long-term follow-up information for patients who received REGN2810 in other clinical studies and to allow re-treatment for eligible patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN2810 | Patients will receive REGN2810 by intravenous (IV) infusion |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2023-11-01
- Completion
- 2023-11-01
- First posted
- 2015-08-11
- Last updated
- 2016-11-07
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02520245. Inclusion in this directory is not an endorsement.